ProxyMiner / Company

Edwards Lifesciences CorpEW

Latest proxy: 2026 · view on SEC ↗ · CIK 0001099800

↓ Export PDF

← All companies

CEO total pay

$17,454,255

Mr. Zovighian · 2025

Say on pay

Not disclosed

Use Ask for the underlying narrative

CEO pay ratio

CD&A

194 to 1

Item 402(u) section may live outside the CD&A

Compensation committee

CD&A

Compensation and Governance Committee

Per the latest proxy

Filings indexed: 2 · 2026 · 2025

Executive pay

What did they pay them?

From the Summary Compensation Table. Pay mix and YoY are computed from these rows.

Executive	Role	TotalYoY	Pay mix	Salary	Stock	Cash incentive	Other
Mr. Zovighian2025 compensation	Chief Executive Officer and Director	$17,454,255↑ 20%	92% at-risk	$1,192,500	$7,167,024	$2,406,537	$189,085
Mr. Ullem2025 compensation	Corporate Vice President, Chief Financial Officer	$6,050,554↑ 14%	85% at-risk	$807,898	$2,205,238	$966,435	$71,257
Mr. Wood2025 compensation	Former Corporate Vice President and Group President, Transcatheter Aortic Valve Replacement and Surgical Structural Heart	$4,854,339↑ 5%	86% at-risk	$635,919	$1,818,499	$689,382	$61,829
Mr. Chopra2025 compensation	Corporate Vice President, Transcatheter Mitral and Tricuspid Therapies	$4,695,742↑ 26%	84% at-risk	$671,042	$1,764,066	$824,239	$60,611
Mr. Bobo2025 compensation	Corporate Vice President, Strategy & Corporate Development	$4,223,365↑ 13%	81% at-risk	$759,783	$1,378,274	$786,899	$48,580
Ms. Brüls2025 compensation	Corporate Vice President, EMEACLA	$3,732,107	75% at-risk	$726,586	$1,020,334	$719,581	$181,706

Pay mix: base cash incentive equity other

Add to peer comparison →Year-over-year diff →

CD&A excerpt

Compensation discussion & analysis

Opening passage of the loaded filing's CD&A. Use Ask below to query the full text with citations.

This Compensation Discussion and Analysis describes and provides disclosure about the objectives and policies underlying our executive compensation programs. Edwards’ 2025 NEOs are as follows: NEO Names and Current PositionsBernard ZovighianDirector and Chief Executive OfficerScott B. UllemCorporate Vice President, Chief Financial OfficerDonald E. Bobo, Jr.Corporate Vice President, Strategy & Corporate DevelopmentAnnette BrülsCorporate Vice President, Europe, Middle East, Africa, Canada and Latin AmericaDaveen ChopraCorporate Vice President, Transcatheter Mitral and Tricuspid Therapies, Surgical and Implantable Heart Failure ManagementLarry L. Wood*Former Corporate Vice President and Group President, Transcatheter Aortic Valve Replacement and Surgical Structural Heart * Mr. Wood resigned on September 1, 2025. Executive Summary Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them…

Read the full CD&A on SEC.gov ↗

Peer comparison

Who they benchmark against

Click any peer to jump to their proxy. Peers we haven't ingested yet kick off an import on click.

Peer Group
15 members · 9 in ProxyMiner
GEHC · GE HealthCare Technologies Inc.TFX · TELEFLEX INCCOO · COOPER COMPANIES, INC.ISRG · INTUITIVE SURGICAL INCA · AGILENT TECHNOLOGIES, INC.DXCM · DEXCOM INCMDT · Medtronic plcALGN · ALIGN TECHNOLOGY INCRMD · RESMED INCBAX · BAXTER INTERNATIONAL INCSYK · STRYKER CORPIDXX · IDEXX LABORATORIES INC /DEZBH · ZIMMER BIOMET HOLDINGS, INC.BSX · BOSTON SCIENTIFIC CORPILMN · ILLUMINA, INC.

Governance

Policy guardrails

hedging
prohibited
“Prohibition on Pledging and Hedging”
pledging
prohibited
“Prohibition on Pledging and Hedging”
stock ownership guidelines
present
“Stock Ownership Guidelines and Holding Requirement”
change in control
Connection with a Change in Control(1)
“Connection with a Change in Control(1)”
compensation consultant
independent
“Independent Compensation Consultant”
compensation committee
Compensation and Governance Committee
“The Compensation and Governance Committee”

Performance markers

Metric facts

revenue
$2.35
“if actual performance falls short of the minimum level for that goal. 2025 Company Financial Performance Measures* Percentage of Financial Measure AchievementMinimum (25%)Target (100%)Maximum (175%)Actual (%)Revenue Grow…”
annual incentive payout
107%
“Annual Cash Incentive Plan Funding—Individual Performance”
performance equity mix
11.5%
“Performance-Based RSUs ("PBRSUs")Annual Cash Incentive CompensationLong-Term Equity CompensationDetermined by multiplying financial measure achievement by KOD achievement by achievement of individual Performance Objectiv…”
time equity mix
50%
“The 2025 long-term incentive awards granted to each of our NEOs were weighted 50% stock options, 25% PBRSUs, and 25% time-based RSUs.”
ceo pay ratio
194 to 1
“our employees (excluding our CEO). Based on SEC rules for this disclosure and applying the methodology described below, we have determined that our CEO’s total compensation for 2025 was 17,454,255, and the median of the …”
median employee compensation
—
“of our employees (excluding our CEO) to be 194 to 1. The median employee’s total annual compensation for 2025 was determined using the same rules that apply to reporting the compensation of our NEOs (including our CEO) i…”

Ask

Anything about Edwards Lifesciences Corp’s 2026 proxy

Answers are grounded in the loaded filing and cite specific artifacts. Bring your own free Google AI Studio key.

Loading the Ask interface…